Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 821-826

  Lewiecki, E M ^a   Cooper, C ^b,c   Thompson, E ^d   Hartl, F ^e   Mehta, D ^f   Papapoulos, S E ^g  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION;

AGED; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77950660843     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02335.x     Document Type: Article

References (19)

1. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 356 : 1809 1822.
2. Heckbert SR, Li G, Cummings SR et al. Use of alendronate and risk of incident atrial fibrialltion in women. Arch Intern Med 2008 168 : 826 831.
3. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009 265 : 581 592.
4. Cummings SR, Schwartz AV, Black DM et al. Alendronate and atrial fibrillation. N Engl J Med 2007 356 : 1895 1896.
5. Karam R, Camm J, McLung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007 16 : 712 713.
6. Chesnut CH III., Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 19 : 1241 1249.
7. Reginster J-Y, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006 65 : 654 661.
8. Eisman JA, Civitelli R, Adami S et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA Study. J Rheumatol 2008 35 : 488 497.
9. Recker R, Stakkestad JA, Chesnut CH III. et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 34 : 890 899.
10. Barrett J, Worth E, Bauss F et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 44 : 951 965.
11. Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001 285 : 2370 2375.
12. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 357 : 1799 1809.
13. Sørensen HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008 336 : 813 816.
14. Bunch TJ, Anderson JL, May HT et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009 103 : 824 828.
15. Grosso A, Douglas I, Hingorani A et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: A self-controlled case-series safety analysis. PLoS ONE 2009 4 : e4720. Epub 2009 Mar 6.
16. Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm (accessed January 2010).
17. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation. Drug Saf 2009 32 : 219 228.
18. Van Wagoner DR, Nerbonne JM. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 2000 32 : 1101 1117.
19. Rosen CJ. Severe hypocalcaemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Eng J Med 2003 348 : 1503 1504.